FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jean-Claude Bystryn

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Living Beings

Mouse

Concepts & Ideas

Treatment Outcome

Co-author Network

Publications

TOP 3
Annette Czernik; Jean-Claude Bystryn; siavash Toosi; Sergei A Grando
Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.
siavash Toosi; Genevieve Torres; Nancy Habib; Sandra R Reynolds; Jean-Claude Bystryn
Serum levels of inhibitors of apoptotic proteins (IAPs) change with IVIg therapy in pemphigus.
Margarita Lolis; siavash Toosi; Annette Czernik; Jean-Claude Bystryn
Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jean-Claude Bystryn (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Annette Czernik; Jean-Claude Bystryn; siavash Toosi; Sergei A Grando
Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.
Autoimmunity 2012;45(1):111-8.
2011: siavash Toosi; Genevieve Torres; Nancy Habib; Sandra R Reynolds; Jean-Claude Bystryn
Serum levels of inhibitors of apoptotic proteins (IAPs) change with IVIg therapy in pemphigus.
The Journal of investigative dermatology 2011;131(11):2327-9.
2011: Margarita Lolis; siavash Toosi; Annette Czernik; Jean-Claude Bystryn
Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies.
Journal of the American Academy of Dermatology 2011;64(3):484-9.
2010: siavash Toosi; Jean-Claude Bystryn
Does adalimumab cause bullous pemphigoid?
Clinical and experimental dermatology 2010;35(7):795.
2010: siavash Toosi; Jean-Claude Bystryn
Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid.
Medical hypotheses 2010;74(4):727-8.
2009: Misha Rosenbach; Dedee F Murrell; Jean-Claude Bystryn; Sam Dulay; Sarah Dick; Steven S Fakharzadeh; Russell Hall; Neil J Korman; Julie Lin; Joyce Okawa; Amit G Pandya; Aimee S Payne; Mathew Rose; David S Rubenstein; David Woodley; Carmela C Vittorio; Benjamin B Werth; Erik A Williams; Lynne Taylor; Andrea B Troxel; Victoria P Werth
Reliability and convergent validity of two outcome instruments for pemphigus.
The Journal of investigative dermatology 2009;129(10):2404-10.
2009: Sergei A Grando; Jean-Claude Bystryn; Alexander I Chernyavsky; Marina Frusić-Zlotkin; Robert Gniadecki; Roberta Lotti; Yoram Milner; Mark R Pittelkow; Carlo Pincelli
Apoptolysis: a novel mechanism of skin blistering in pemphigus vulgaris linking the apoptotic pathways to basal cell shrinkage and suprabasal acantholysis.
Experimental dermatology 2009;18(9):764-70.
2009: Nancy Habib; Jean-Claude Bystryn
An alternate explanation for the decrease in pemphigus antibodies with combination treatment of double-filtration plasmapheresis and IVIg.
European journal of dermatology : EJD 2009;19(2):190; author reply 191.
2009: Caroline Othoro; Dean Johnston; Rebecca Lee; Jonathan Soverow; Jean-Claude Bystryn; Elizabeth H Nardin
Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod.
Infection and immunity 2009;77(2):739-48.
2008: Jean-Claude Bystryn
Comparative effectiveness of azathioprine or mycophenolate mofetil as an adjuvant for the treatment of bullous pemphigoid.
Archives of dermatology 2008;144(7):946.
2008: Dédée F Murrell; Sarah Dick; A R Ahmed; Masayuki Amagai; Maria A Barnadas; Luca Borradori; Jean-Claude Bystryn; Giuseppe Cianchini; Luis A Diaz; David P Fivenson; Russell Hall; Karen E Harman; Takashi Hashimoto; Michael Hertl; Nico Hunzelmann; Pilar Iranzo; Pascal Joly; Marcel F Jonkman; Yasuo Kitajima; Neil J Korman; Linda K Martin; Daniel Mimouni; Amit G Pandya; Aimee S Payne; David S Rubenstein; Hiroshi Shimizu; Animesh Sinha; David Sirois; Detlef Zillikens; Victoria P Werth
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.
Journal of the American Academy of Dermatology 2008;58(6):1043-6.
2008: Annette Czernik; Jean-Claude Bystryn
Kinetics of response to conventional treatment in patients with pemphigus vulgaris.
Archives of dermatology 2008;144(5):682-3.
2008: Annette Czernik; Jean-Claude Bystryn
Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibodies.
Archives of dermatology 2008;144(5):658-61.
2008: Annette Czernik; Ernst H Beutner; Jean-Claude Bystryn
Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus.
Journal of the American Academy of Dermatology 2008;58(5):796-801.
2007: Annette Czernik; Jean-Claude Bystryn
Does imiquimod work in infantile hemangiomas?
Journal of the American Academy of Dermatology 2007;57(3):535; author reply 536.
2007: Daniel Weitz; Jean-Claude Bystryn
Frequency of shifts over time in the profile of antidesmoglein antibodies in pemphigus vulgaris.
Archives of dermatology 2007;143(8):1073-4.
2007: Dean Johnston; Bushra Zaidi; Jean-Claude Bystryn
TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.
Cancer immunology, immunotherapy : CII 2007;56(8):1133-41.
2007: Jean-Claude Bystryn
A confusing message will not improve the detection of melanoma.
Archives of dermatology 2007;143(6):806; author reply 806-7.
2007: Jean-Claude Bystryn
Increasing ratio of thin to thick melanoma lesions: pathogenesis and early detection of this cancer.
Archives of dermatology 2007;143(6):804; author reply 804-5.
2006: Jean-Claude Bystryn; Diane Jiao
IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris.
Autoimmunity 2006;39(7):601-7.
2006: Paulo Rowilson Cunha; Jean-Claude Bystryn; Emerson Palmeira L Medeiros; Josenildo R de Oliveira
Sensitivity of indirect immunofluorescence and ELISA in detecting intercellular antibodies in endemic pemphigus foliaceus (Fogo Selvagem).
International journal of dermatology 2006;45(8):914-8.
2006: Jean-Claude Bystryn; Megan M Moore
Cutaneous pemphigus vulgaris: what causes it?
Journal of the American Academy of Dermatology 2006;55(1):175-6; author reply 176-7.
2006: Sandra R Reynolds; Irene J Vergilis; Michael Szarek; Soldano Ferrone; Jean-Claude Bystryn
Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy?
International journal of cancer. Journal international du cancer 2006;119(1):157-61.
2006: Dean Johnston; Sandra R Reynolds; Jean-Claude Bystryn
Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice.
Cancer immunology, immunotherapy : CII 2006;55(4):412-9.
2006: Dean Johnston; Jean-Claude Bystryn
Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine.
Vaccine 2006;24(11):1958-65.
2006: Jean-Claude Bystryn; Sergei A Grando
A novel explanation for acantholysis in pemphigus vulgaris: the basal cell shrinkage hypothesis.
Journal of the American Academy of Dermatology 2006;54(3):513-6.
2005: Jean-Claude Bystryn; Jennifer L Rudolph
IVI g TREATMENT OF PEMPHIGUS: how it works and how to use it.
The Journal of investigative dermatology 2005;125(6):1093-8.
2005: Jean-Claude Bystryn; Jennifer L Rudolph
Pemphigus.
Lancet 2005;366(9479):61-73.
2005: Jean-Claude Bystryn; Jennifer L Rudolph
Emerging melanoma vaccines.
Expert opinion on emerging drugs 2005;10(2):393-402.
2005: Dean Johnston; Jean-Claude Bystryn
Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice.
Cancer immunology, immunotherapy : CII 2005;54(4):345-50.
2005: Jean-Claude Bystryn; Jennifer L Rudolph
Why is the mortality of bullous pemphigoid greater in Europe than in the US?
The Journal of investigative dermatology 2005;124(3):xx-xxi.
2005: Jean-Claude Bystryn; Sandra R Reynolds
Melanoma vaccines: what we know so far.
Oncology (Williston Park, N.Y.) 2005;19(1):97-108; discussion 108, 111-2, 115.
2004: Paulo Rowilson Cunha; Josenildo Rodrigues de Oliveira; Maria José Salles; Jasmin Jamora; Jean-Claude Bystryn
Pemphigus vulgaris with involvement of the cervix treated using thalidomide therapy.
International journal of dermatology 2004;43(9):682-4.
2003: Macrene Alexiades-Armenakas; Marisa Baldassano; Benji Bince; Victoria P Werth; Jean-Claude Bystryn; Hideko Kamino; Nicholas A Soter; Andrew G Franks
Tumid lupus erythematosus: criteria for classification with immunohistochemical analysis.
Arthritis and rheumatism 2003;49(4):494-500.
2003: Maria Jasmin J Jamora; Diane Jiao; Jean-Claude Bystryn
Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris.
Journal of the American Academy of Dermatology 2003;48(6):976-7.
2003: Sandra R Reynolds; Jeff Albrecht; Richard L Shapiro; Daniel F Roses; Matthew N Harris; Andrew Conrad; Anne Zeleniuch-Jacquotte; Jean-Claude Bystryn
Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1497-502.
2003: Maria Jasmin Jamora; Brent D Wainwright; Shane A Meehan; Jean-Claude Bystryn
Improved identification of potentially dangerous pigmented skin lesions by computerized image analysis.
Archives of dermatology 2003;139(2):195-8.
2003: Sandra R Reynolds; Anne Zeleniuch-Jacquotte; Richard L Shapiro; Daniel F Roses; Matthew N Harris; Dean Johnston; Jean-Claude Bystryn
Vaccine-induced CD8+ T-cell responses to MAGE-3 correlate with clinical outcome in patients with melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):657-62.
2002: Jean-Claude Bystryn
Emerging melanoma vaccines.
Expert opinion on emerging drugs 2002;7(2):213-21.
2002: Jean-Claude Bystryn
Vaccines for melanoma.
Dermatologic clinics 2002;20(4):717-25.
2002: Jean-Claude Bystryn
Can nondermatologists really recognize potentially dangerous skin lesions as well as dermatologists?
Archives of dermatology 2002;138(10):1378.
2002: Jean-Claude Bystryn; Ayse Akman; Diane Jiao
Limitations in enzyme-linked immunosorbent assays for antibodies against desmogleins 1 and 3 in patients with pemphigus.
Archives of dermatology 2002;138(9):1252-3.
2002: Jean-Claude Bystryn; Diane Jiao; Steven Natow
Treatment of pemphigus with intravenous immunoglobulin.
Journal of the American Academy of Dermatology 2002;47(3):358-63.
2002: Jean-Claude Bystryn; Brent D Wainwright; Jerome L Shupack
Oral and topical corticosteroids in bullous pemphigoid.
The New England journal of medicine 2002;347(2):143-5; author reply 143-5.
2001: Jean-Claude Bystryn; Anne Zeleniuch-Jacquotte; Ruth Oratz; Richard L Shapiro; Matthew N Harris; Daniel F Roses
Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1882-7.
2001: Elizabeth K Hale; Jean-Claude Bystryn
Laryngeal and nasal involvement in pemphigus vulgaris.
Journal of the American Academy of Dermatology 2001;44(4):609-11.
2001: Jean-Claude Bystryn; J Albrecht; Sandra R Reynolds; M C Rivas; Ruth Oratz; Richard L Shapiro; Daniel F Roses; Matthew N Harris; A Conrad
Decrease in circulating tumor cells as an early marker of therapy effectiveness.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2001;158():204-7.
2000: Sandra R Reynolds; E Celis; A Sette; Ruth Oratz; Richard L Shapiro; Dean Johnston; M Fotino; Jean-Claude Bystryn
Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
Journal of immunological methods 2000;244(1-2):59-67.
2000: Dimitris Ioannides; Fotis Chrysomallis; Jean-Claude Bystryn
Ineffectiveness of cyclosporine as an adjuvant to corticosteroids in the treatment of pemphigus.
Archives of dermatology 2000;136(7):868-72.
2000: Jean-Claude Bystryn
Dermatology manpower needs.
Dermatologic clinics 2000;18(2):303-12, x.
2000: E K Hale; Jean-Claude Bystryn
Relation between skin temperature and location of facial lesions in seborrheic dermatitis.
Archives of dermatology 2000;136(4):559-60.
2000: Dimitris Ioannides; B D Golden; J P Buyon; Jean-Claude Bystryn
Expression of SS-A/Ro and SS-B/La antigens in skin biopsy specimens of patients with photosensitive forms of lupus erythematosus.
Archives of dermatology 2000;136(3):340-6.
2000: A Herbst; Jean-Claude Bystryn
Patterns of remission in pemphigus vulgaris.
Journal of the American Academy of Dermatology 2000;42(3):422-7.
1999: Elizabeth K Hale; Jean-Claude Bystryn
Atypical herpes simplex can mimic a flare of disease activity in patients with pemphigus vulgaris.
Journal of the European Academy of Dermatology and Venereology : JEADV 1999;13(3):221-3.
1999: Kevin J McElwee; DJ Tobin; Jean-Claude Bystryn; Lloyd E King; John P Sundberg
Alopecia areata: an autoimmune disease?
Experimental dermatology 1999;8(5):371-9.
1999: Diane Jiao; Jean-Claude Bystryn
Relation between antibodies to BP180 and gender in bullous pemphigoid.
Journal of the American Academy of Dermatology 1999;41(2 Pt 1):269-70.
1999: Z Xie; D Chen; Diane Jiao; Jean-Claude Bystryn
Vitiligo antibodies are not directed to tyrosinase.
Archives of dermatology 1999;135(4):417-22.
1999: P Rowilson-Cunha; Jean-Claude Bystryn
Sensitivity of indirect immunofluorescence and immunoblotting for the detection of intercellular antibodies in endemic pemphigus foliaceus (fogo selvagem).
International journal of dermatology 1999;38(1):41-5.
1998: Sandra R Reynolds; E Celis; A Sette; Ruth Oratz; Richard L Shapiro; Dean Johnston; M Fotino; Jean-Claude Bystryn
HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(12):6970-6.
1998: Paulo Rowilson Cunha; P V Thomazeski; E Hipólito; N S Michalany; Jean-Claude Bystryn
Bullous pemphigoid in a 2-month-old infant.
International journal of dermatology 1998;37(12):935-8.
1998: Diane Jiao; Jean-Claude Bystryn
Antibodies to desmoplakin in a patient with pemphigus foliaceous.
Journal of the European Academy of Dermatology and Venereology : JEADV 1998;11(2):169-72.
1998: Jean-Claude Bystryn
Vaccines for melanoma. Design strategies and clinical results.
Dermatologic clinics 1998;16(2):269-75.
1998: J Applebaum; S Reynolds; J Knispel; Ruth Oratz; R Shapiro; Jean-Claude Bystryn
Identification of melanoma antigens that are immunogenic in humans and expressed in vivo.
Journal of the National Cancer Institute 1998;90(2):146-9.
1998: Kevin J McElwee; Dawnalyn Boggess; T Olivry; RF Oliver; D Whiting; DJ Tobin; Jean-Claude Bystryn; Lloyd E King; John P Sundberg
Comparison of alopecia areata in human and nonhuman mammalian species.
Pathobiology : journal of immunopathology, molecular and cellular biology 1998;66(2):90-107.
1997: M B Abdel-Naser; S K Hann; Jean-Claude Bystryn
Oral psoralen with UV-A therapy releases circulating growth factor(s) that stimulates cell proliferation.
Archives of dermatology 1997;133(12):1530-3.
1997: Paulo Rowilson Cunha; Diane Jiao; Jean-Claude Bystryn
Simultaneous occurrence of herpetiform pemphigus and endemic pemphigus foliaceus (fogo selvagem).
International journal of dermatology 1997;36(11):850-4.
1997: Jean-Claude Bystryn
Immune mechanisms in vitiligo.
Clinics in dermatology 1997;15(6):853-61.
1997: Sandra R Reynolds; Ruth Oratz; Richard L Shapiro; P Hao; Z Yun; M Fotino; S Vukmanović; Jean-Claude Bystryn
Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.
International journal of cancer. Journal international du cancer 1997;72(6):972-6.
1997: DJ Tobin; John P Sundberg; Lloyd E King; Dawnalyn Boggess; Jean-Claude Bystryn
Autoantibodies to hair follicles in C3H/HeJ mice with alopecia areata-like hair loss.
The Journal of investigative dermatology 1997;109(3):329-33.
1997: Diane Jiao; Jean-Claude Bystryn
Sensitivity of indirect immunofluorescence, substrate specificity, and immunoblotting in the diagnosis of pemphigus.
Journal of the American Academy of Dermatology 1997;37(2 Pt 1):211-6.
1997: DJ Tobin; S K Hann; M S Song; Jean-Claude Bystryn
Hair follicle structures targeted by antibodies in patients with alopecia areata.
Archives of dermatology 1997;133(1):57-61.
1996: D J Tobin; Jean-Claude Bystryn
Different populations of melanocytes are present in hair follicles and epidermis.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 1996;9(6):304-10.
1996: Jean-Claude Bystryn; Richard L Shapiro; M Harris; Daniel F Roses; Ruth Oratz
Use of vaccines in treatment of malignant melanoma.
Clinics in dermatology 1996;14(4):337-41.
1996: Jean-Claude Bystryn; N M Steinman
The adjuvant therapy of pemphigus. An update.
Archives of dermatology 1996;132(2):203-12.
1995: D J Tobin; Jean-Claude Bystryn
Immunity to hair follicles in alopecia areata.
The Journal of investigative dermatology 1995;104(5 Suppl):13S-14S.
1995: N Schultz; Ruth Oratz; D Chen; Anne Zeleniuch-Jacquotte; G Abeles; Jean-Claude Bystryn
Effect of DETOX as an adjuvant for melanoma vaccine.
Vaccine 1995;13(5):503-8.
1995: J Cui; Jean-Claude Bystryn
Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells.
Archives of dermatology 1995;131(3):314-8.
1995: J Cui; D Chen; M L Misfeldt; R W Swinfard; Jean-Claude Bystryn
Antimelanoma antibodies in swine with spontaneously regressing melanoma.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 1995;8(1):60-3.
1995: J Cui; Y Arita; Jean-Claude Bystryn
Characterization of vitiligo antigens.
Pigment cell research / sponsored by the European Society for Pigment Cell Research and the International Pigment Cell Society 1995;8(1):53-9.
1995: K Miller; G Abeles; Ruth Oratz; Anne Zeleniuch-Jacquotte; J Cui; Daniel F Roses; Matthew N Harris; Jean-Claude Bystryn
Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine.
Cancer 1995;75(2):495-502.
1995: Jean-Claude Bystryn
Clinical activity of a polyvalent melanoma antigen vaccine.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 1995;139():337-48.
1995: D J Tobin; S R Colen; Jean-Claude Bystryn
Isolation and long-term culture of human hair-follicle melanocytes.
The Journal of investigative dermatology 1995;104(1):86-9.
1994: S Q Gao; Jean-Claude Bystryn
A novel bullous pemphigoid antigen (BP125) located in the deeper layers of the basement membrane zone.
Archives of dermatology 1994;130(7):873-8.
1994: D J Tobin; Norman Orentreich; D A Fenton; Jean-Claude Bystryn
Antibodies to hair follicles in alopecia areata.
The Journal of investigative dermatology 1994;102(5):721-4.
1994: S Q Gao; Jean-Claude Bystryn
Identification of a novel basement membrane antigen (p84) defined by sera with antibodies to both the epidermal and dermal side of split skin.
The Journal of investigative dermatology 1994;102(2):236-40.
1994: D Johnston; S el Rouby; Jean-Claude Bystryn
Identification of melanoma cell surface antigens immunogenic in mice.
Cancer biotherapy 1994;9(1):29-38.
1993: Jean-Claude Bystryn
Immunogenicity and clinical activity of a polyvalent melanoma antigen vaccine prepared from shed antigens.
Annals of the New York Academy of Sciences 1993;690():190-203.
1993: Jean-Claude Bystryn; E Hodak; S Q Gao; J V Chuba; E L Amorosi
A paraneoplastic mixed bullous skin disease associated with anti-skin antibodies and a B-cell lymphoma.
Archives of dermatology 1993;129(7):870-5.
1993: J Cui; Y Arita; Jean-Claude Bystryn
Cytolytic antibodies to melanocytes in vitiligo.
The Journal of investigative dermatology 1993;100(6):812-5.
1992: Jean-Claude Bystryn; M Henn; J Li; S Shroba
Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
Cancer research 1992;52(21):5948-53.
1992: D Johnston; Seth J Orlow; E Levy; Jean-Claude Bystryn
Induction of B16 melanoma melanogenesis by a serum-free synthetic medium.
Experimental cell research 1992;201(1):91-8.
1992: Jean-Claude Bystryn; Ruth Oratz; Daniel F Roses; M Harris; M Henn; R Lew
Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma.
Cancer 1992;69(5):1157-64.
1992: J Cui; Jean-Claude Bystryn
An improved europium release assay for complement-mediated cytolysis.
Journal of immunological methods 1992;147(1):13-9.
1992: D Ioannides; Jean-Claude Bystryn
Immunofluorescence abnormalities in lichen planopilaris.
Archives of dermatology 1992;128(2):214-6.
1992: J Cui; R Harning; M Henn; Jean-Claude Bystryn
Identification of pigment cell antigens defined by vitiligo antibodies.
The Journal of investigative dermatology 1992;98(2):162-5.
1992: Y Niimi; X J Zhu; Jean-Claude Bystryn
Identification of cicatricial pemphigoid antigens.
Archives of dermatology 1992;128(1):54-7.
1991: R Harning; J Cui; Jean-Claude Bystryn
Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo.
The Journal of investigative dermatology 1991;97(6):1078-80.
1991: Ruth Oratz; Jean-Claude Bystryn
Immunotherapy of malignant melanoma.
Dermatologic clinics 1991;9(4):669-82.
1991: R Harning; E Mainolfi; Jean-Claude Bystryn; M Henn; V J Merluzzi; Robert Rothlein
Serum levels of circulating intercellular adhesion molecule 1 in human malignant melanoma.
Cancer research 1991;51(18):5003-5.
1991: D Johnston; Jean-Claude Bystryn
Effect of cell wall skeleton and monophosphoryl lipid A adjuvant on the immunogenicity of a murine B16 melanoma vaccine.
Journal of the National Cancer Institute 1991;83(17):1240-5.
1991: Y Niimi; Z X Zhu; Jean-Claude Bystryn
Identification of basement membrane zone antigens defined by antibodies that react to both the epidermal and dermal side of 1 M sodium chloride split skin.
The Journal of investigative dermatology 1991;97(2):312-7.
1991: Ruth Oratz; M Dugan; Daniel F Roses; Matthew N Harris; James Speyer; Howard Hochster; J Weissman; M Henn; Jean-Claude Bystryn
Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Cancer research 1991;51(14):3643-7.
1991: Jean-Claude Bystryn; J Tamesis
Immunologic aspects of hair loss.
The Journal of investigative dermatology 1991;96(5):88S-89S.
1991: D Ioannides; Prodromos Hytiroglou; Robert G Phelps; Jean-Claude Bystryn
Regional variation in the expression of pemphigus foliaceus, pemphigus erythematosus, and pemphigus vulgaris antigens in human skin.
The Journal of investigative dermatology 1991;96(2):159-61.
1990: X J Zhu; Y Niimi; Jean-Claude Bystryn
Molecular identification of major and minor bullous pemphigoid antigens.
Journal of the American Academy of Dermatology 1990;23(5 Pt 1):876-80.
1990: X J Zhu; Y Niimi; Jean-Claude Bystryn
Identification of a 160-kD molecule as a component of the basement membrane zone and as a minor bullous pemphigoid antigen.
The Journal of investigative dermatology 1990;94(6):817-21.
1990: X J Zhu; Y Niimi; Jean-Claude Bystryn
Epidermolysis bullosa acquisita. Incidence in patients with basement membrane zone antibodies.
Archives of dermatology 1990;126(2):171-4.
1990: R Tan-Lim; Jean-Claude Bystryn
Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies.
Journal of the American Academy of Dermatology 1990;22(1):35-40.
1989: Jean-Claude Bystryn
Autoimmune diseases of the skin.
Allergy proceedings : the official journal of regional and state allergy societies 1989;10(6):393-6.
1989: Ruth Oratz; C Cockerell; James Speyer; M Harris; Daniel F Roses; Jean-Claude Bystryn
Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine.
Journal of biological response modifiers 1989;8(4):355-8.
1989: Jean-Claude Bystryn
Immunosurveillance and melanoma.
The Journal of investigative dermatology 1989;92(5 Suppl):318S-320S.
1989: Jean-Claude Bystryn
Serum antibodies in vitiligo patients.
Clinics in dermatology 1989;7(2):136-45.
1989: D Johnston; Jean-Claude Bystryn
Immunogenicity and tumor protective activity of B16 melanoma vaccines.
Molecular biotherapy 1989;1(4):218-22.
1989: Jean-Claude Bystryn
Immune mechanisms in vitiligo.
Immunology series 1989;46():447-73.
1988: Jean-Claude Bystryn
Plasmapheresis therapy of pemphigus.
Archives of dermatology 1988;124(11):1702-4.
1988: Jean-Claude Bystryn
Therapy of pemphigus.
Seminars in dermatology 1988;7(3):186-94.
1988: Jean-Claude Bystryn; Ruth Oratz; Matthew N Harris; Daniel F Roses; F M Golomb; James Speyer
Immunogenicity of a polyvalent melanoma antigen vaccine in humans.
Cancer 1988;61(6):1065-70.
1988: Jean-Claude Bystryn; S Pfeffer
Vitiligo and antibodies to melanocytes.
Progress in clinical and biological research 1988;256():195-206.
1987: L Sison-Fonacier; Jean-Claude Bystryn
Heterogeneity of pemphigus vulgaris antigens.
Archives of dermatology 1987;123(11):1507-10.